Table 2.

comparison of miR-126-5p and miR-13 expression levels in patients with different characteristics.

Clinicopathological features	n	miR-126-5p	t	P	miR-13	t	P
Gender
Male	95	15.51 ± 2.68	0.848	0.396	19.57 ± 2.30	1.066	0.288
Female	108	15.79 ± 2.01			19.90 ± 2.11
Age (years old)
<50	120	16.91 ± 1.73	0.279	0.780	18.91 ± 1.73	0.296	0.772
≥50	83	16.84 ± 1.79			18.84 ± 1.63
Lactate dehydrogenase
<320	92	15.65 ± 1.29	14.972	<0.001	18.06 ± 1.22	0.584	0.560
≥320	111	17.76 ± 0.67			17.91 ± 2.20
WBC (×109/L)
<10	21	15.44 ± 1.16	0.109	0.914	18.39 ± 1.25	0.057	0.955
≥10	182	15.48 ± 1.64			18.37 ± 1.56
HGB (g/L)
<90	151	16.06 ± 2.47	6.282	<0.001	18.92 ± 1.25	5.320	<0.001
≥90	52	18.74 ± 3.13			20.21 ± 2.09
PLT (×109/L)
<50	149	16.81 ± 1.67	0.815	0.416	19.73 ± 2.54	1.105	0.271
≥50	54	17.05 ± 2.29			20.16 ± 2.18
Proportion of bone marrow primordial cells
<0.6	130	15.98 ± 2.01	0.171	0.864	17.67 ± 2.38	1.642	0.102
≥0.6	73	16.03 ± 1.98			18.21 ± 1.99
Hepatomegaly
Yes	142	16.28 ± 2.11	0.254	0.800	18.32 ± 2.62	1.119	0.264
No	61	16.36 ± 1.92			17.81 ± 3.68
Splenomegaly
Yes	155	17.87 ± 2.50	0.144	0.885	19.29 ± 2.75	1.621	0.107
No	48	17.93 ± 2.57			20.03 ± 2.81
Lymph node enlargement
Yes	136	15.37 ± 2.56	0.635	0.526	18.91 ± 2.07	0.400	0.689
No	67	15.61 ± 2.48			19.04 ± 2.38
NPM1
Mutant type	127	17.23 ± 2.19	4.872	<0.001	19.03 ± 2.16	6.081	<0.001
Wild type	76	18.96 ± 2.83			20.82 ± 1.79
FLT3-ITD
Positive	125	17.95 ± 2.14	0.200	0.842	18.55 ± 2.03	0.664	0.504
Negative	78	18.01 ± 1.99			18.76 ± 2.42
Complete remission
Yes	181	19.38 ± 1.86	5.147	<0.001	18.53 ± 2.29	4.620	<0.001
No	22	17.21 ± 1.93			16.17 ± 2.10